Eli Lilly's GLP-1 pill Foundayo alleviates sleep apnea in late-stage studies
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Eli Lilly’s GLP-1 pill Foundayo alleviated sleep apnea in two late-stage studies, reducing breathing disruptions by 17.8 events per hour on the apnea-hypopnea index compared to 4.5 for placebo. Furthermore, 28% of patients achieved remission or mild disease, versus 13% on placebo, though it appears less effective than Zepbound.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu